mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2022.05.08.22274797: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has several limitations. First, in the absence of empirical evidence of randomised controlled trials, we estimated the efficacy of the mRNA-based booster against the Omicron variant based on a synthesis of evidence from real-world data. We conducted various sensitivity analyses to account for the uncertainty in parameter …
SciScore for 10.1101/2022.05.08.22274797: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has several limitations. First, in the absence of empirical evidence of randomised controlled trials, we estimated the efficacy of the mRNA-based booster against the Omicron variant based on a synthesis of evidence from real-world data. We conducted various sensitivity analyses to account for the uncertainty in parameter estimation based on real-world data. Second, we assumed that the efficacy of COVID-19 vaccines begins to wane in 3 months. In reality, the efficacy of vaccines is more likely to gradually decline without a clear cut-off. This assumption may have led to an overestimate of vaccine efficacy in the short term, and an underestimate in the long term. Third, we did not consider the other non-mRNA-based COVID-19 vaccines (e.g., AstraZeneca or Novavax) in Australia. However, AstraZeneca is no longer recommended for use as the booster dose for people who received a primary vaccination course of the AstraZeneca COVID-19 vaccine, and Novavax is rarely used (<1%) in Australia. Finally, given limited public health resources and escalating health inequity during the pandemic, there is a need for more targeted, local-based vaccine and booster distribution strategies that can achieve a tradeoff between cost-effectiveness and equity. The design of such strategies, while beyond the scope of this work, will be critical in alleviating the burden of COVID-19, reducing health care costs, and achieving equity. In conclusion, Australia’s current COVID-19 booster strategy is...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
